The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

VERTEX SECOND QUARTER 2024 FINANCIAL RESULTS AUGUST 1, 2024 ©2024 Vertex Pharmaceuticals Incorporated AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2024 Vertex Pharmaceuticals Incorporated 2 SAFE HARBOR ...

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer, President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer. Susie Lisa - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Jessica Fye - J.P. Morgan Evan Seigerman - BMO Capital Markets Chris Raymond - Piper Sandler Teren ...

Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.57%. A quarter ago, it was expected that this drugmaker would post earnings of $4.10 per share when it actually produced earnings of $4.76, delivering a surprise of 16.10%. Over the last four quarters, th ...

Vertex Reports Second Quarter 2024 Financial Results — Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025; additionally, MAA submissions validated in EU and U.K. — — FDA accepted NDA for suzetrigine (VX-548) for moderate-to-severe acute pain with Priority Review and PDUFA target action date of ...

Vertex Pharmaceuticals Incorporated (VRTX) is scheduled to report second-quarter 2024 results on Aug 1, after market close. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $2.65 billion, while the same for earnings is pinned at $4.04 per share. Factors Shaping Upcoming Results In the past 30 days, estimates for Vertex's 2024 earnings per share (EPS) have remained constant at $16.78. During the same time frame, the forecast for the company's 2025 EPS has deteriorated from ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $490.80, reflecting a +0.1% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily loss of 2.32%. Elsewhere, the Dow saw a downswing of 1.25%, while the tech-heavy Nasdaq depreciated by 3.64%. Coming into today, shares of the drugmaker had gained 3.48% in the past month. In that same time, the Medical sector gained 0.32%, while the S&P 500 gained 1.79%. The upcoming earnings release of Vertex ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's +1.8% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 3.9% over this period. Now the key question is: Where could the stock be headed in the near term? Earni ...

Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 1, 2024. The company is expected to report EPS of $4.14, up 6.43% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $2.64 billion, indicating a 6.01% increase compared to the same quarter of the previous year. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), po ...

- Three-year extension of collaboration to use genomics to accelerate drug discovery - - The range of therapeutic areas and genomic data insights will be expanded and the companies will also explore using genomic risk to better define patient subgroups - OXFORD, England, July 16, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company's collaboration with Vertex Pharmaceuticals Incorporated (Ve ...